FDA Approve Telaprevir (Incivek) to Treat Hepatitis C
On 23 May 2011, the FDA approved telaprevir (Incivek) to be used in combination with peginterferon alfa and ribavirin to treat hepatitis C genotype 1. Telaprevir is the second direct acting antiviral drug against the hepatitis C virus to be approved.
Telaprevir is indicated in adult patients with compensated liver disease, including cirrhosis, who are treatment-naive (patients who have not received interferon-based drug therapy for their infection) or who have previously been treated with interferon-based treatment and not responded adequately, including prior null responders, partial responders, and relapsers.
The approval of telaprevir is based on safety and efficacy data in approximately 2250 adult subjects who were previously untreated (ADVANCE and ILLUMINATE) or who had failed previous peginterferon alfa and ribavirin therapy (REALIZE) in clinical studies.
The following points should be considered when initiating treatment with telaprevir:
Source: FDA listserve (23 May 2011).
For full prescribing details se the product lable at:
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)